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Edited by Felix WielandAbstract Heterotrimeric G proteins are lipid-modiﬁed, periph-
eral membrane proteins that function at the inner surface of the
plasma membrane (PM) to relay signals from cell-surface
receptors to downstream eﬀectors. Cellular traﬃcking pathways
that direct nascent G proteins to the PM are poorly deﬁned. In
this report, we test the proposal that G proteins utilize the
classical exocytic pathway for PM targeting. PM localization of
the G protein heterotrimers asb1c2 and aqb1c2 occurred inde-
pendently of treatment of cells with Brefeldin A, which disrupts
the Golgi, or expression of Sar1 mutants, which prevent the
formation of endoplasmic reticulum to Golgi transport vesicles.
Moreover, the palmitoylation of aq was unaﬀected by Brefeldin
A treatment, even though the palmitoylation of SNAP25 was
blocked by Brefeldin A. Non-palmitoylated mutants of as and aq
failed to stably bind to bc and displayed a dispersed cytoplasmic
localization when co-expressed with bc. These ﬁndings support a
reﬁned model of the PM traﬃcking pathway of G proteins,
involving assembly of the heterotrimer at the endoplasmic
reticulum and transport to the PM independently of the Golgi.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Heterotrimeric G proteins (abc) need to be tethered to the
inner leaﬂet of the plasma membrane (PM) where they are
coupled to receptors and relay signals to downstream eﬀectors.
Numerous studies have identiﬁed requirements for PM local-
ization of the a and bc subunits. Lipid modiﬁcation, namely
myristoylation and/or palmitoylation for a and isoprenylation
for bc, is an essential membrane targeting signal [1]. In addi-
tion, both a and bc require interaction with each other for
eﬃcient PM localization [2–4]. Much less well understood is a
cellular traﬃcking pathway by which the G protein subunits
reach the PM after synthesis. The bc complex localizes at the
endoplasmic reticulum (ER) when expressed without a, while* Corresponding author. Fax: +1-215-923-2117.
E-mail address: P_Wedegaertner@mail.jci.tju.edu
(P.B. Wedegaertner).
Abbreviations: G protein, guanine nucleotide binding protein; BFA,
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doi:10.1016/j.febslet.2004.04.062co-expression of a leads to strong PM localization of abc [2,5].
These results and others have suggested a model whereby a
and bc interact to form a heterotrimer at an endomembrane
location before reaching the PM, with the ER as an essential
component of the traﬃcking pathway. An unresolved ques-
tion, however, is whether heterotrimeric G proteins traﬃc to
the PM via the Golgi apparatus using the classical secretory/
exocytic pathway.
The Golgi apparatus is a highly polarized compartment
where proteins from the ER are further processed, sorted,
packed, and released to a speciﬁc subcellular location. Al-
though most integral membrane and secreted proteins require
the Golgi for proper transport, both Golgi-dependent and
Golgi-independent traﬃcking has been described for lipid-
modiﬁed, peripheral membrane proteins. Sensitivity to brefel-
din A (BFA) has implicated the Golgi complex in PM targeting
and/or palmitoylation of some peripheral membrane-bound
proteins [6]. For instance, SNAP25, a synaptic SNARE pro-
tein, requires a functional exocytic pathway, and its transport
to the PM and palmitoylation are blocked by BFA [7]. On the
other hand, PM targeting but not palmitoylation of the tyro-
sine kinase Lck was inhibited by BFA treatment [8]. Other
proteins bypass Golgi as exempliﬁed by the tyrosine kinase Fyn
whose PM targeting and palmitoylation are unaﬀected by BFA
[9]. Thus, it appears that multiple cellular pathways exist for
targeting peripheral membrane proteins to the PM. For G
protein a subunits of the ai family, which undergo both myri-
stoylation and palmitoylation, the eﬀect of BFA has been
studied to some extent. PM localization of transfected az was
not blocked by BFA [3], and neither was palmitoylation of
endogenous ai and ao [7]. Relatively little is known about the
requirement of a functional Golgi complex in PM targeting of
bc, and for PM targeting and palmitoylation of a subunits,
such as as and aq, that are palmitoylated but not myristoylated.
In the present study, we investigated a traﬃcking pathway
for the G protein heterotrimers asb1c2 and aqb1c2, focusing on
the potential involvement of the Golgi. PM targeting of both
the a and bc subunits was insensitive to BFA. We also dem-
onstrate that dominant negative mutants of Sar1, a GTPase
required for the formation of vesicles that move from the ER
to Golgi, blocked PM localization of a G protein-coupled re-
ceptor but failed to prevent asb1c2 and aqb1c2 from traveling
to the PM. Furthermore, palmitoylation of aq occurs even in
the presence of BFA treatment, while palmitoylation of
SNAP25 requires an intact Golgi in HEK293 cells. Lastly,
palmitoylation-deﬁcient mutants of as and aq failed to form ablished by Elsevier B.V. All rights reserved.
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palmitoylation of a occurs early in the traﬃcking pathway and
is required for heterotrimer formation.Fig. 1. BFA prevents PM localization of b2-AR but not b1c2. (a) and
(b) HEK293 cells were transfected with 100 ng of a plasmid containing
a GFP-tagged Golgi marker protein, p230-C98. 16 h after transfection,
cells were incubated in the absence (a) and presence (b) of 10 lg/ml of
BFA for 3 h and then ﬁxed. (c) and (d) HEK293 cells transiently
transfected (12 h) with an expression vector encoding b2-AR (300 ng)
were incubated in the absence (c) or presence (d) of 10 lg/ml of BFA
for 5 h and then ﬁxed. (e) and (f) Plasmids encoding b1 (300 ng) and c2
(100 ng) were transfected into HEK293 cells in conjunction with
pcDNA3 containing as (600 ng). 27 h after transfection, cells were
incubated in the absence (e) or presence (f) of 10 lg/ml of BFA for 5 h
and then ﬁxed. Transfected proteins were visualized by immunoﬂuo-
rescence staining as described under Section 2 using a rabbit polyclonal
anti-b2-AR antibody for b2-AR and a mouse monoclonal anti-myc
9E10 antibody for bc.2. Materials and methods
2.1. Cell culture
HEK293 and COS7 cells were obtained from the American Type
Culture Collection (Manassas, VA) and grown in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine serum and
maintained at 37 C in a 95% air, 5% CO2-humidiﬁed atmosphere.
2.2. Constructs
Wild type as (HA-tagged) or b1 (myc- and His-tagged) in pcDNA3.1
and non-tagged c2 in pcDNA3 were described previously. The ex-
pression vector for vsvg-tagged Sar1T39N was provided by Stephen J.
Gould (Johns Hopkins University). Sar1H79G (vsvg-tagged) was
created from Sar1T39N using QuickChange site-directed mutagenesis
kit (Stratagene, La Jolla, CA). pEGFP-C1 containing p230-C98 was
given by Paul A. Gleeson (Monash University). The SNAP-25/GFP/
myc construct was given by Maurine E. Linder (Washington Univer-
sity). The b-AR construct was provided by Jeﬀery L. Benovic (Kimmel
Cancer Center).
2.3. Transfection
Unless otherwise noted, cells were seeded 1 day before transfection.
An indicated amount of DNA constructs was transfected into cells
using FuGene 6 (Roche, Indianapolis, IN) according to the manu-
facturer’s protocol.
2.4. Antibodies
The anti-HA mouse monoclonal antibody 12CA5 was from Roche
and the anti-Myc mouse monoclonal antibody 9E10 was from Co-
vance (Berkeley, CA). The anti-b2-AR polyclonal antibody was pro-
vided by Mark von Zastrow (University of California, San Francisco).
Anti-vsvg polyclonal and monoclonal P5D4 antibodies were from
Sigma (St. Louise, MO). Goat anti-rabbit or goat anti-mouse anti-
bodies conjugated with either Alexa 488 or Alexa 594 was from Mo-
lecular Probes (Eugene, OR).
2.5. Immunoﬂuorescence microscopy
Cells were ﬁxed with 3.7% formaldehyde in phosphate-buﬀered
saline (PBS) for 15 min and permeabilized by incubation in blocking
buﬀer (2.5% non-fat milk and 1% Triton X-100 in TBS) for 20 min.
Cells were then incubated with primary antibodies indicated in
blocking buﬀer for 1 h. The cells were washed with blocking buﬀer
and incubated in a 1:250 dilution of a goat anti-mouse or a goat anti-
rabbit antibody conjugated with either Alexa 488 or Alexa 594 for 30
min. The coverslips were washed with 1% Triton X-100 in TBS,
rinsed in distilled water, and mounted on glass slides with Prolong
Antifade reagent (Molecular Probes, Eugene, OR). Microscopy was
performed with an Olympus BX60 microscope and a Sony DKC-5000
digital camera, or using an Olympus BX61 microscope and an OR-
CA-ER (Hamamatsu, Bridgewater, NJ) cooled CCD camera con-
trolled by Slidebook version 4.0 (Intelligent Imaging Innovations,
Denver, CO). Images were transferred to Adobe Photoshop for digital
processing.
2.6. BFA treatment
In order to determine the appropriate time to treat transfected cells
with BFA, time-course ﬁxation and immunostaining experiments were
performed. We found that b2-AR could be detected at the PM 16–18 h
after transfection. However, when asb1c2 was expressed, PM locali-
zation of as and b1c2 was observed 31–33 h after transfection. Based
on these experiments, we added BFA to cells 12 or 27 h after trans-
fection for b2-AR or asb1c2, respectively. Cells were treated with BFA
for 5 h before formaldehyde ﬁxation.
2.7. Ni–NTA pull down of b1(c2)
Taking advantage of the hexahistidine tagged amino terminus of b1,
Ni–NTA pull down of b1c2 and associated a was carried out as de-
scribed previously [2].2.8. Palmitoylation assay
aq in conjunction with b1c2, or SNAP-25, was transfected into COS7
cells. 36 h after transfection, the cells were metabolically labeled with
[3H]palmitate for 3 h in the absence or presence of BFA (10 lg/ml) and
then lysed. The cell lysate was subject to immunoprecipitation using
9E10 antibody for SNAP25 or Ni–NTA pull down for aq. The samples
were separated by SDS–PAGE and transferred onto polyvinylidene
diﬂuoride membrane. The membrane was sprayed with EnHance
(Perkin–Elmer Life Science) and exposed to Hyperﬁlm MP (Amer-
sham Biosciences) at )80 C for 7–10 days. After ﬂuorography, the
protein was detected by immunoblotting using an antibody indicated.3. Results
3.1. PM targeting of asb1c2 is insensitive to BFA treatment
To examine the involvement of the ER-Golgi pathway, we
examined the eﬀects of BFA on localization of the G protein
heterotrimer asb1c2 in HEK293 cells. BFA, a metabolite of the
fungus Eupenicillium brefeldianum, speciﬁcally causes a rapid
disassembly and redistribution of the Golgi complex and has
been used widely as a tool to demonstrate the involvement of
the Golgi in a particular pathway or process. Fluorescence
microscopy was utilized to locate the subcellular distribution
of transfected proteins. A Golgi marker (pEGFP-p230-C98)
displayed characteristic Golgi localization in the absence of
BFA (Fig. 1a), while treatment of cells with BFA led to scat-
tered distribution of the markers (Fig. 1b), indicating that
BFA caused complete disassembly of the Golgi apparatus in
HEK293 cells. We utilized the b2-AR receptor as a control for
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be targeted to the PM through the exocytic pathway, and thus
its PM localization should be blocked by BFA. As expected,
BFA eﬃciently blocked PM traﬃcking of b2-AR (Figs. 1c
and d). In contrast, BFA did not prevent PM localization of a
G protein heterotrimer in HEK293 cells. b1c2 transiently ex-
pressed in conjunction with as exhibited strong PM localiza-
tion in the absence or presence of BFA (Figs. 1e and f).
Likewise, PM localization of as was unaﬀected by BFA
treatment (not shown).
3.2. Sar1-independent PM targeting of heterotrimeric
G proteins
Multiple GTPases are known to regulate vesicular traﬃc in
the exocytic pathway, and one of these, Sar1, plays a pivotal
role in the formation of vesicles that ferry between the ER and
Golgi. Both a GDP-restricted mutant, Sar1T39N, and a GTP-
restricted mutant, Sar1H79G, function as dominant negatives
to prevent vesicle traﬃcking between the ER and Golgi [10–
12]. We tested the eﬀects of these mutants in HEK293 cells
transiently expressing the G protein heterotrimers asb1c2 or
aqb1c2. As a positive control, b2-AR showed little or no PM
localization when co-expressed with Sar1T39N or Sar1H79G
(Figs. 2A, a–c). On the other hand, co-expression of Sar1T39N
or Sar1H79G with asb1c2 or aqb1c2 did not prevent PM lo-
calization of the heterotrimer. b1c2 (Fig. 2A, f–h), as (Fig. 2B,
a and b) and aq (Fig. 2B, d and e) all retained eﬃcient PM
targeting in the presence of Sar1T39N or Sar1H79G. Likewise,Fig. 2. Sar1 mutants prevent PM localization of b2-AR but not heterotrimeric
ng), b1 (300 ng), and c2 (100 ng) (f–j) were transfected into HEK293 cells in th
(250 ng) (b, d, g, and i) or Sar1H79G (250 ng) (c, e, h, and j). (B) Expressio
(600 ng), b1 (300 ng), and c2 (100 ng) (d–f) were transfected into HEK293 c
Sar1T39N (250 ng) (b and c) or Sar1H79G (250 ng) (e and f). 36 h after
transiently expressed proteins using a rabbit polyclonal anti-b2-AR antibody
anti-HA 12CA5 antibody for as and aq, and either a polyclonal or monocloin COS7 cells, SarT39N did not block PM localization of b1c2,
as and aq (data not shown). Thus, the results in Figs. 1 and 2
suggest that at least some heterotrimeric G proteins utilize a
PM traﬃcking pathway that is independent of the ER to Golgi
portion of the classical exocytic pathway.
3.3. Palmitoylation of non-myristoylated a is insensitive to BFA
We next examined whether palmitoylation of aq requires a
functional Golgi. It has been shown that palmitoylation of
both GAP-43 and SNAP25, which like aq are modiﬁed only
with palmitate, is sensitive to BFA [7]. Transfected cells were
metabolically labeled with [3H]palmitate in the absence or
presence of BFA and the level of incorporated palmitate was
visualized by ﬂuorography. Consistent with earlier reports
[7,13], palmitoylation of SNAP25 was greatly impaired by
BFA treatment (Fig. 3, lane 2) and, as a matter of fact, lack of
the modiﬁcation resulted in a change of apparent molecular
weight as previously described [7]. However, virtually no dif-
ference in incorporation of [3H]palmitate into aq (Fig. 3, lanes
3 and 4) was seen in the absence and presence of BFA, indi-
cating palmitoylation of the non-myristoylated a subunits
occurs independently of the ER-Golgi pathway.
3.4. Palmitoylation defective non-myristoylated a subunits are
not targeted to the Golgi complex
To further examine a potential role for the Golgi in palmi-
toylation of G proteins, localization of a palmitoylation de-
fective mutant of as and aq was examined. It has been reportedG proteins. (A) Expression vectors for b2-AR (300 ng) (a–e) or as (600
e absence (a and f) or presence of either pcDNA3 containing Sar1T39N
n vectors for as (600 ng), b1 (300 ng), and c2 (100 ng) (a–c) or for aq
ells in the absence (a and d) or presence of either pcDNA3 containing
transfection, immunoﬂuorescence staining was performed to visualize
for b2-AR, a monoclonal anti-myc 9E10 antibody for bc, a monoclonal
nal anti-vsvg antibody for Sar1 mutants.
Fig. 5. bc pull down of wild type and palmitoylation-deﬁcient a sub-
units. Plasmids containing as (lane 1), asC3S (lane 2), as, b1, and c2
(lane 3), asC3S, b1, and c2 (lane 4), aq (lane 5), aqC9,10S (lane 6), aq,
b1, and c2 (lane 7), or aqC9,10S, b1, and c2 (lane 8) were transfected
into HEK293 cells. Transfection was carried out in 6-cm plates using
3 lg of total plasmid DNA at a 6:3:1 ratio of a:b:c. 36 h after trans-
fection, the cells were lysed and subjected to a Ni–NTA pull down
assay. Note that the wild type or mutant of as or aq was HA-tagged,
while the b1 subunit contained a myc and His tag. Whole cell lysates
(top panel) and eluates were analyzed by SDS–PAGE and Western
blotting for the a subunit (middle panel) using 12CA5 anti-HA
monoclonal antibody or for the b subunit (bottom panel) using 9E10
anti-myc monoclonal antibody.
Fig. 3. BFA inhibits palmitoylation of SNAP25 but not aq. COS7 cells
were transfected with constructs for SNAP25 (600 ng) (lanes 1 and 2),
or aq (600 ng), b1 (300 ng), and c2 (100 ng) (lanes 3 and 4). 30 h after
transfection, cells were labeled for 3 h with 1 mCi/ml of [3H]palmitate
in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of BFA (10
lg/ml) and lysed. SNAP25 was immunoprecipitated using the 9E10
monoclonal antibody and aq bound to b1c2 was pulled down with Ni–
NTA magnetic agarose beads. The samples were separated by SDS–
PAGE and transferred onto a polyvinylidene diﬂuoride membrane.
The PVDF membrane was exposed to a ﬁlm at )80 C (top panel).
Subsequently, the membrane was subjected to Western blotting for
SNAP25 and aq (bottom panel).
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corporation of myristate, is localized at the Golgi when ex-
pressed with bc. We tested whether the non-myristoylated a
subunits are targeted to Golgi when their cysteine sites of
palmitoylation are mutated. asC3S or aqC9,10S, b1 and c2
were transfected into HEK293 cells in conjunction with a
Golgi marker and immunoﬂuorescence staining was per-
formed. In contrast to wild type as or aq, which displayed
prominent PM localization (Fig. 2B, a and d), asC3S orFig. 4. Palmitoylation-deﬁcient a subunits are not found at the Golgi.
Expression vectors for asC3S (600 ng), b1 (300 ng), and c2 (100 ng) (a,
b, g, and h), aqC9,10S (600 ng), b1 (300 ng), and c2 (100 ng) (c and d),
or as (600 ng), b1 (300 ng), and c2 (100 ng) (e and f) were transfected
into HEK293 cells (a–d) or COS7 cells (e–h) in conjunction with a
Golgi marker, pEGFP-C1-p230-C98 (100 ng). Cells were ﬁxed and the
a subunits were visualized by immunoﬂuorescence staining as de-
scribed under Section 2. The 12CA5 anti-HA monoclonal antibody
was used to probe for as or aq.aqC9,10S exhibited dispersed distribution throughout the cy-
toplasm and, moreover, neither of them was colocalized with
the Golgi marker (Figs. 4a and c). Similarly, in COS7 cells,
wild type as (Fig. 4e) or aq (data not shown) was targeted to
the PM, while palmitoylation defective as (Fig. 4g) or aq (data
not shown) exhibited a cytoplasmic and perinuclear distribu-
tion with no colocalization with the Golgi marker (Fig. 4h).
Thus, the results of Figs. 3 and 4 suggest that the Golgi is not
the site of palmitoylation of as or aq.
3.5. bc did not pull down non-palmitoylated a
Lastly, we looked at whether palmitoylation of a is required
for assembly of a stable abc trimer. b1c2, in which b1 contains a
hexahistidine tag, was expressed in conjunction with wild type
or palmitoylation site mutants of as and aq, and then b1c2 was
pulled down from cell lysates with Ni–NTA magnetic agarose
beads. Immunoblotting of the pull down for the presence of as
or aq reveals the ability of the a subunit to stably bind b1c2.
Using this assay, wild type as (Fig. 5, lane 3) and wild type aq
(Fig. 5, lane 7) eﬀectively interacted with b1c2; however, neither
asC3S (Fig. 5, lane 4) nor aqC9,10S (Fig. 5, lane 8) could be
detected in the pull down, indicating that the palmitoylation
deﬁcient mutants do not form a stable complex with b1c2. In
order to assure no non-speciﬁc binding to the beads, we carried
out parallel experiments onHEK293 cells transiently expressing
wild type or mutant a in the absence of bc. No bands corre-
sponding to a subunits were detected in these controls (Fig. 5,
middle panel, lanes 1, 2, 5, and 6), thus verifying the assay. In
addition, equivalent amounts of b1c2 were pulled down in the
diﬀerent samples (Fig. 5, bottom panel, lanes 3, 4, 7, and 8).
4. Discussion
Data presented herein demonstrate that the expressed G
protein heterotrimers asb1c2 and aqb1c2 arrive at the PM in-
dependently of the classical exocytic pathway. Perturbants of
traﬃc via this pathway had no eﬀect on PM localization of the
S. Takida, P.B. Wedegaertner / FEBS Letters 567 (2004) 209–213 213a and bc subunits and on palmitoylation of a. BFA did not
prevent PM localization of bc or as when expressed together,
whereas it completely impeded that of b2-AR (Fig. 1). Our
result is in close agreement with the previous ﬁnding that BFA
treatment did not prevent accumulation of newly synthesized
bc in a detergent insoluble fraction [14,15]. We here further
demonstrated that dominant negative Sar1 mutants did not
aﬀect PM targeting of abc (Fig. 2). Collectively, the data with
BFA and Sar1 mutants suggest that at least some G protein
heterotrimers travel to the PM in a Golgi-independent fashion.
The existence of a BFA-insensitive, Sar1-independent traf-
ﬁcking pathway in mammalian cells has been recently re-
ported. One of the palmitoylated proteins in lipid rafts,
ﬂotillin-1/reggie-2, was found to traverse to the PM through
such a Golgi-independent pathway [10]. In addition, several
other palmitoylated proteins, including Saccharomyces cerevi-
siae Ras2p, which utilizes palmitate and a farnesyl group as
membrane targeting signals, have been shown to reach the PM
by a route other than the classical secretory pathway [6,16].
Consistent with Golgi-independent abc traﬃcking, we found
that BFA treatment did not impede palmitoylation of non-
myristoylated a, as exempliﬁed by aq (Fig. 3). This result agrees
with a recent report indicating that palmitoylation of ai, a
subunit that undergoes both myristoylation and palmitoyla-
tion, is insensitive to BFA treatment [7]. The subcellular loca-
tion(s) of palmitate attachment to a subunits has not been well
deﬁned. Identiﬁcation of a relevant palmitoyltransferase will be
a key component to further deﬁne the traﬃcking pathway of G
proteins. One study deﬁned a Ga palmitoyltransferase activity
that was enriched in a PM preparation and demonstrated that
the presence of bc enhanced enzymatic palmitoylation of a [17].
These results led to proposals that heterotrimer assembly and
palmitoylation occur at the PM. On the other hand, a palmi-
toyltransferase for yeast Ras2p has been recently localized to
ERmembranes [18], and a palmitoyltransferase for yeast casein
kinase is found at the Golgi [19]. Clearly, palmitoylation of at
least some peripheral membrane proteins occurs at intracellular
locations, and diﬀerent proteins utilize diﬀerent pathways to
reach their proper membrane destination [6,20,21].
Does palmitoylation of a occur prior to abc trimer formation
or after? Our results indicate that b1c2 is unable to form a stable
complex with palmitoylation defective asC3S and aqC9,10S
(Fig. 4). These results are consistent with previous in vitro
studies using puriﬁed proteins showing that palmitoylated as
was able to bind the bc dimer substantially more tightly than
non-palmitoylated as [22]. These data suggest the possibility
that the bc and a subunits form a complex after palmitoylation
of a. We and others previously reported that bc transits to the
ER after undergoing prenylation and, in fact, is localized there
when expressed alone [2,5]. Moreover, co-expression of wild
type a resulted in eﬃcient PM localization of bc, whereas
palmitoylation defective amutants, asC3S and aqC9,10S, failed
to do so, with bc remaining at the ER [2]. Taken together, and
given the ER localization of a palmitoyltransferase for Ras2p,
it is tempting to speculate that palmitoylation of the a subunit
may take place at ER. However, molecular mechanisms by
which a travels to ER need to be clariﬁed. In this regard, we did
not observe clear localization of the palmitoylation defective
cysteine-to-serine a mutants at the ER.
A recent study speculated that G protein heterotrimer as-
sembly and a subunit palmitoylation occur at Golgi mem-
branes, based on colocalization at the Golgi of bc and apalmitoylation defective ai2 [5]. However, in our hands, Golgi
localization was not seen when bc was co-expressed with
asC3S or aqC9,10S (Fig. 4), and BFA failed to block palmi-
toylation of aq and PM traﬃcking of as and bc. These
contrasting results may suggest that diﬀerent G protein het-
erotrimers can take diﬀerent routes to the PM. G proteins
containing a subunits that are both myristoylated and palmi-
toylated (e.g., ai) may transit to the PM via the Golgi, in
contrast to Golgi-independent PM targeting of heterotrimers
containing non-myristoylated a subunits (e.g., as and aq).
Arguing against this possibility, however, are demonstrations
that palmitoylation of endogenous ai and PM targeting of az
are insensitive to BFA treatment [3,7].
The precise nature of the Golgi-independent G protein
traﬃcking remains to be further investigated. Also, still un-
known is the existence of accessory molecules which help
shuttle the subunits to the PM, particularly after formation of
the abc trimer. Our results do not rule out the involvement of
such proteins. In conclusion, we demonstrated that both PM
localization of the G protein subunits and palmitoylation of
the non-myristoylated a subunit occur independently of the
conventional exocytic pathway. The reﬁned model of PM
traﬃcking of the G protein subunits is consistent with for-
mation of an abc trimer at ER and traﬃcking to the PM
without transit to the Golgi apparatus.References
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